



Farmacia  
**HOSPITALARIA**

Órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

[www.elsevier.es/farmaciahospitalaria](http://www.elsevier.es/farmaciahospitalaria)



## Review

# Immunotherapy in advanced endometrial cancer with microsatellite instability: A systematic review

Cristina Moreno-Ramos<sup>a</sup>, Manuel David Gil-Sierra<sup>b</sup> and María del Pilar Briceño-Casado<sup>b,\*</sup>

<sup>a</sup> Subdirección de Farmacia, Servicios Centrales de Extremadura, Mérida, Spain

<sup>b</sup> Servicio de Farmacia, Hospital Universitario de Puerto Real, Puerto Real, Spain

## ARTICLE INFO

### Article history:

Received 16 January 2025

Accepted 8 May 2025

Available online xxxx

### Keywords:

Endometrial cancer

Microsatellite instability

Systematic review

Pembrolizumab

Lenvatinib

## ABSTRACT

**Background:** Endometrial cancer with microsatellite instability (MSI) involves 30% of diagnosed cases. There are some uncertainty about second-line treatment, after platinum-based first-line treatment. The aim of this study was to perform a systematic review on the scientific evidence of immunotherapies for endometrial cancer with MSI.

**Methods:** PubMed and Embase databases were searched up to May 28, 2024. We included clinical trials about patients with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H) diagnosed with advanced and/or metastatic endometrial cancer who had previously received platinum-based chemotherapy. Clinical trials with a dMMR or MSI-H population size of less than 10 patients were discarded. Efficacy results in overall survival, progression-free survival and objective response rate were used to determine the most interesting drugs. A safety analysis of therapies was developed.

**Results:** Fifty-four studies were found in a systematic search. Fourteen clinical trials were selected. The following drugs were evaluated: pembrolizumab monotherapy, pembrolizumab plus lenvatinib, durvalumab, durvalumab-tremelimumab combination, dostarlimab, nivolumab and avelumab. The greatest numerical efficacy effect was achieved by pembrolizumab, followed by pembrolizumab in combination with lenvatinib. The most common adverse events were fatigue and gastrointestinal disorders.

**Conclusion:** The efficacy of pembrolizumab and pembrolizumab-lenvatinib regimen appears promising. However, studies with larger sample size, longer follow-up and comparative design with subgroup analysis based on differences in microsatellite repair mechanisms are needed for proper therapeutic positioning.

© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Inmunoterapia en cáncer de endometrio avanzado con inestabilidad de microsatélites: Revisión sistemática

## RESUMEN

**Introducción:** El cáncer de endometrio con inestabilidad de microsatélites (MSI) representa el 30% de casos diagnosticados. Existe incertidumbre sobre el tratamiento de segunda línea, tras una primera línea basada en platino. El objetivo de este estudio fue realizar una revisión sistemática sobre la evidencia científica de los tratamientos inmunoterápicos para el cáncer de endometrio con MSI.

**Métodos:** Se realizó una búsqueda en la base de datos PubMed y Embase hasta el 28 de mayo de 2024. Se incluyeron ensayos clínicos con pacientes que presentasen deficiencia de reparación de emparejamiento erróneos (dMMR) o alta inestabilidad de microsatélites (MSI-H) diagnosticados de cáncer de endometrio avanzado y/o metastásico que habían recibido previamente quimioterapia basada en platino. Se descartaron los ensayos clínicos con un tamaño de población de dMMR o MSI-H inferior a 10 pacientes. Para determinar los fármacos de mayor interés se emplearon los resultados de eficacia en supervivencia global, supervivencia libre de progresión y tasa de respuesta objetiva. Se realizó un análisis sobre la seguridad de las terapias.

**Resultados:** Se encontraron 54 estudios, de los cuales 14 ensayos clínicos fueron incluidos. Los siguientes fármacos fueron evaluados: pembrolizumab en monoterapia, pembrolizumab más lenvatinib, durvalumab,

### Palabras clave:

Cáncer de endometrio

Inestabilidad de microsatélites

Revisión sistemática

Pembrolizumab

Lenvatinib

\* Corresponding author at: Servicio de Farmacia, Hospital Universitario de Puerto Real, C/Romería, 7, 11510 Puerto Real, Cádiz, Spain.

E-mail address: [pilarbricenocasado@gmail.com](mailto:pilarbricenocasado@gmail.com) (M.P. Briceño-Casado).

<https://doi.org/10.1016/j.farma.2025.05.008>

1130-6343/© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

durvalumab en combinación con tremelimumab, dostarlimab, nivolumab y avelumab. El mayor efecto numérico en eficacia se alcanzó con pembrolizumab, seguido de pembrolizumab en combinación con lenvatinib. Los eventos adversos más frecuentes fueron fatiga y alteraciones gastrointestinales.

**Conclusiones:** La eficacia de pembrolizumab y del régimen pembrolizumab-lenvatinib parece prometedora. Sin embargo, son necesarios estudios con mayor tamaño muestral, seguimiento más prolongado y diseño comparativo con análisis de subgrupos basado en diferencias en los mecanismos de reparación de microsatélites para un posicionamiento terapéutico adecuado.

© 2025 Los Autores. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Farmacia Hospitalaria (S.E.F.H.). Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Endometrial cancer (EC) is the sixth most common neoplasm diagnosed in women. This pathology caused 97,000 deaths worldwide in 2020.<sup>1</sup> Some cases of EC have been associated with microsatellite instability (MSI). The prevalence of MSI in EC is estimated to be around 30% of diagnosed cases.<sup>2</sup>

The mechanism of microsatellite (MS) generation could be explained by DNA displacement during replication, or by a mismatch between the coding strand and the template strand during replication and repair process. This would result in the erroneous addition or deletion of one or more base pairs.<sup>3</sup> Mismatch repair (MMR) system—one of DNA repair mechanisms in healthy cells—maintains the number of MS repeats at every cell division. Deficiencies in MMR prevent cells from regulating these sequences and MSI are originated.<sup>3,4</sup> Absence of one or more MMR proteins (MSH2, MSH6, MLH1 and PMS2) results in an MMR deficiency (dMMR). According to the frequency of error production, three types of MSI are distinguished: high MSI (MSI-H), low MSI (MSI-L) and MS stability (MSS).<sup>3</sup> On the other hand, the presence of all MMR proteins confers a competent system (MMRp).<sup>5</sup> A significant proportion of MSI-H tumours present dMMR, whereas those characterised as MSI-L appear to manifest MMRp. Some studies suggest that tumours with MSI-L or MSS features do not differ in their molecular or physiological characterisation.<sup>6,7</sup>

Molecular investigation of genetic defects has allowed the differentiation of another gene related to MS, whose mutation leads to high error accumulation. Disruptions in exonuclease domain of polymerase  $\epsilon$  (POLE) gene are associated with MSI-H.<sup>3</sup>

To date, platinum-based chemotherapy has been a common first-line treatment in advanced EC.<sup>8</sup> On the other hand, EC characterised by the presence of MSI has been associated with increased neoantigen load and increased CD3(+), CD8(+) and programmed cell death protein 1 (PD-1) in tumour infiltrating lymphocytes compared to EC with MSS.<sup>9</sup> Likewise, increased expression of programmed death ligand-1 (PD-L1) has been observed in intraepithelial immune cells of MSI tumours. These findings have led to the use of therapies targeting PD-1 or PD-L1 inhibition in the treatment of EC with MSI. The aim of this work was to develop a systematic review of literature on the scientific evidence of immunotherapeutic drugs for EC with MSI previously treated with platinum-based chemotherapy.

## Methods

### Literature search and study selection

PICOS model was applied to perform the literature search: patients, intervention, comparator, objective and study design.<sup>10</sup> Patients with dMMR or MSI-H diagnosed with advanced and/or metastatic EC who had previously received platinum-based chemotherapy were selected. All immunotherapies used as intervention and all comparators were included. Selected endpoints were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). In terms of design, clinical trials (CTs) with a minimum of 10 target patients were

included. Conference communications were excluded due to a lack of information.

Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)<sup>11</sup> methodology was used to conduct a review in PubMed® and Embase® databases up to 28 May 2024. Filter 'clinical trials' was applied with the following terms: [microsatellite instability OR mismatch repair deficient] AND endometrial cancer. "PICO tool" was used on the Embase® database according to the PICOS model described above. The following search criteria were applied in Embase® database: ('endometrium cancer'/exp. AND 'microsatellite instability' OR 'mismatch repair deficient'/exp) AND 'immunotherapy'/exp. AND ('objective response rate'/exp. OR 'progression free survival'/exp. OR 'overall survival'/exp) AND 'clinical trial'/exp. AND [<1966–2024]/py.

Two investigators conducted the search independently. Disagreements were resolved by discussion between study authors. Titles and abstracts were screened to exclude results that did not meet the study inclusion criteria. Full articles were reviewed in the eligibility process. Studies were accepted in English or Spanish.

### Data extraction

Data from all studies were extracted and validated by two investigators. The following variables were collected from trials: authors and publication dates, study design, histology, stage, treatment lines, median follow-up, number of patients, treatments used as intervention and control. For efficacy endpoints, ORR values, median PFS and OS, confidence intervals and relative values in comparative CTs were collected. Regarding safety, the most frequent adverse events (AEs) of any grade, those of grade 3 or higher and immune-mediated AEs were recorded. Treatment reductions, discontinuations and deaths due to AEs were also obtained in those studies where available.

### Data analysis

Importance of outcomes was assigned on the basis of clinical relevance for analysis of the efficacy of therapeutic alternatives. Final endpoint considered most important was OS (time from randomisation to death from any cause). PFS (time from randomisation to progression or death from any cause) was established as the surrogate endpoint of greatest value. ORR, defined as the proportion of patients with partial or complete response according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1,<sup>12</sup> was analysed as the least relevant surrogate endpoint. The most interesting therapeutic alternatives were determined based on the above-mentioned efficacy criteria.

In terms of safety, AEs were assessed in patients who had received at least one dose of the drug during CT. AEs of grade 3 or higher were considered the most important due to their difficult management. The most frequent AEs (regardless of grade) and immune-mediated AEs were checked. Other data such as reductions, discontinuations or deaths due to treatment were reviewed.

The selected studies were grouped according to the treatment regimens used.

## Risk of bias

Availability of exclusive data on the target population (advanced and/or metastatic EC who had previously received platinum-based chemotherapy) or subgroup analyses were evaluated. Quality of data from the target population (previously treated patients) is superior to the quality of results from populations involving patients from different lines of treatment. Inappropriate interpretations of aggregate data could influence the conclusions. Sample sizes of CTs and follow-up periods were also checked. More reliable results are obtained from large sample sizes and long follow-up periods. Adequate sample sizes and patient follow-ups allow minimising unrealistic dispersion of results, as well as determining an acceptable number of events.

Cochrane risk of bias assessment tool was applied to the included studies,<sup>13</sup> including eight domains: confounding bias; selection of participants into the study (or into the analysis) bias; classification of interventions bias; deviations from intended interventions bias; missing data bias; measure the outcome bias; selection of the reported results; and overall bias. Two investigators independently assessed the risk of bias.

## Results

### Literature search, study selection and data extraction

A total of 54 records were found in the systematic search, of which 40 publications were excluded. Reasons for exclusion of studies were as follows: 12 were developed in a different clinical context, 10 did not show efficacy outcome data for pharmacological treatments, 6 were conference communications, 4 included less than ten target patients, 3 were not a CT, 2 were duplicated, 2 did not evaluate immunotherapy and 1 showed different efficacy endpoints. Finally, 14 studies were included.<sup>5,14–20,22,23,25,26,28,30</sup> Fig. 1 shows the systematic review conducted according to PRISMA methodology. Two of the included studies<sup>14,17</sup> were extension studies of Marabelle et al. trial.<sup>16</sup> The designs of included studies were: 8 non-randomised phase II studies, 3 non-randomised phase I studies, 1 randomised phase II study, 1 randomised phase III study and 1 randomised phase Ib/II study. All trials included patients who had received at least one first-line platinum-based treatment. Among CTs, 14.3% included patients with advanced EC,<sup>22,26</sup> 14.3% metastatic disease,<sup>15,18</sup> and 71.4% both.<sup>5,14,16,17,19,20,23,25,28,30</sup> All studies reported patient follow-up data (median values between 6 and 42.6 months). Sample size of included patients ranged from 11 to 143. The regimens analysed were: pembrolizumab monotherapy, pembrolizumab plus lenvatinib combination, durvalumab, durvalumab plus

tremelimumab, dostarlimab, nivolumab and avelumab. Only two trials included a comparator arm. Table 1 shows the data and results of selected studies.

### Data analysis

The largest numerical effect was achieved for pembrolizumab after a median follow-up of 25.8 months (OS = 40.0 months [95% CI, 25.3–Not Reached]); (PFS = 23.5 months [95% CI, 10.7–NR]); (ORR = 58% [95% CI, 37–78]).<sup>15</sup> Pembrolizumab plus lenvatinib was positioned as another interesting alternative after 12.2 months of follow-up (OS = NR [95% CI, NR–NR]); (PFS = 10.7 months, [95% CI 5.6–NR]); (ORR = 40% [95% CI, 28–53]).<sup>20</sup> No OS data were found in 2 trials (14.3%).<sup>18,23</sup>

### Pembrolizumab

Pembrolizumab is an IgG4 anti-PD-1 monoclonal antibody, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2.<sup>14,15</sup> Multicohort KEYNOTE-158 study showed results on the use of pembrolizumab in patients diagnosed with cancer with MSI-H/dMMR, excluding colorectal cancer.<sup>16</sup> This was a phase II, nonrandomized, multicenter, single-arm CT. Subsequently, two extensions of this study were published including results from D and K cohorts with patients diagnosed of EC with MSI-H/dMMR.<sup>14,17</sup> O'Malley et al.<sup>14</sup> included 90 patients from D (n = 11) and K (n = 79) cohorts. With a median follow-up of 42.6 months (95% CI, 6.4–56.1), ORR was achieved by 48.0% (95% CI, 37.0–60.0) of patients according to an independent radiological committee. The median PFS observed was 13.1 months (95% CI, 4.3–34.4), while the median OS was not reached. Bellone et al.<sup>15</sup> developed an investigation with similar characteristics to KEYNOTE-158 trial. Median follow-up was 25.8 months. An ORR of 58% (95% CI, 37–78) was achieved according to investigator analysis. Median PFS was 23.5 months (95% CI, 10.7–NR), and median OS was 40.0 months (95% CI, 25.3–NR).

Other trials combined pembrolizumab with lenvatinib, such as Makker et al.<sup>18</sup> and Makker et al.<sup>19</sup> Both studies had similar designs: single-arm phase II trial. Patients with MSI-H/dMMR and MSS/MMRp were enrolled. MSS/MMRp was detected in 94 patients by Makker et al.,<sup>19</sup> while 11 patients presented MSI-H/dMMR. ORR based on investigator assessment in MSI-H/dMMR group was 63.6% (95% CI, 30.8–89.1). Median PFS was 18.9 months (95% CI, 4.0–NR), and median OS was not achieved in this MSI-H/dMMR group. Makker et al.<sup>20</sup> was a phase III, randomised, open-label, comparative CT. Pembrolizumab-lenvatinib regimen was evaluated *versus* chemotherapy. ORR achieved in MSI-H/dMMR population was 40% (95% CI, 28–53) in pembrolizumab




Figure 1. Systematic review of literature.

**Table 1**  
Characteristics and efficacy data of studies.

Publication (authors)	Publication date	Study design	Histology	Stage	Treatment line	Follow-up of patients (median number of months, range)	Sample size of target population (number of patients)	Intervention drugs	Comparator regimen	ORR (percentages and 95% CI)	PFS (median number of months and 95% CI) Hazard Ratio (95% CI) in comparative trials	OS (median number of months and 95% CI) Hazard Ratio (95% CI) in comparative trials
André et al. <sup>26</sup>	November, 2023	Non-randomised phase I (basket)	All histologic types except carcinosarcoma and endometrial sarcoma	Advanced (recurrent)	Previously treated patients	29.1 (no range data found)	143	Dostarlimab 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal	No comparator arm	45.5% (37.1–54.0)	6.0 (4.1–18.0)	NR (25.7 – NR)
Rubinstein et al. <sup>23†‡</sup>	February, 2023	Randomised phase II	Endometrioid, serous, undifferentiated, mixed epithelial, mucinous, squamous, transitional cell, adenocarcinoma not otherwise specified and endometrial carcinosarcoma.	Advanced or metastatic (recurrent or persistent)	Previously treated patients	6 (no range data found) <sup>§</sup>	75	Durvalumab 1500 mg and tremelimumab 75 mg every 4 weeks for up to 4 cycles, and then 1500 mg durvalumab every 4 weeks thereafter	Durvalumab 1500 mg every 4 weeks.	<u>Durvalumab and tremelimumab</u> <sup>†‡</sup> 5.3% (1.4–100)  <u>Durvalumab</u> <sup>†‡</sup> 10.8% (4.8–100)	<u>Durvalumab and tremelimumab</u> <sup>†‡</sup> 2.0 (1.75–Inf)  <u>Durvalumab</u> <sup>†‡</sup> 1.9 (1.75–Inf)	No data found <sup>†‡</sup>
Maio et al. <sup>17</sup> ; Extension study Marabelle et al. <sup>16</sup> O'Malley et al. <sup>14</sup> ; Extension study Marabelle et al. <sup>16</sup> Bellone et al. <sup>15</sup>	September, 2022 March, 2022 March, 2022	Non-randomised phase II Non-randomised phase II Non-randomised phase II	All histologic types except carcinosarcoma and sarcoma All histologic types except carcinosarcoma and sarcoma All histologic types except sarcomas and mesenchymal tumours	Advanced or metastatic Advanced or metastatic Metastatic (recurrent)	Previously treated patients Previously treated patients Previously treated patients	37.5 (0.2–55.6) 42.6 (6.4–56.1) 25.8 (no range data found)	68 79 24	Pembrolizumab 200 mg once every 3 weeks for 35 cycles Pembrolizumab 200 mg once every 3 weeks for 35 cycles Pembrolizumab 200 mg once every 3 weeks for 35 cycles	No comparator arm No comparator arm No comparator arm	48.5% (36.2–61.0) 48.0% (37.0–60.0). 58% (37–78)	13.1 (4.9–34.4) 13.1 (4.3–34.4) 23.5 (10.7–NR)	NR (32.4–NR) NR (27.2–NR) 40.0 (25.3–NR)
Makker et al. <sup>20</sup>	February, 2022	Randomised phase III	All histologic types except carcinosarcoma and sarcoma	Advanced, or metastatic (recurrent)	Previously treated patients	<u>Lenvatinib and pembrolizumab</u> 12.2 (no range data found)  <u>Chemotherapy</u> 10.7 (no range data found)	130	Lenvatinib 20 mg once daily and pembrolizumab 200 mg once every 3 weeks for 35 cycles	Chemotherapy (doxorubicin or paclitaxel)	<u>Lenvatinib and pembrolizumab</u> 40% (28–53)  <u>Chemotherapy</u> 12% (5–23)	<u>Lenvatinib and pembrolizumab</u> 10.7 (5.6 – NR)  <u>Chemotherapy</u> 3.7 (3.1–4.4)  HR 0.36 (95% CI, 0.23–0.57) <i>P</i> < 0.001	<u>Lenvatinib and pembrolizumab</u> NR (NR – NR)  <u>Chemotherapy</u> 8.6 (5.5–12.9)  HR 0.37 (95% CI, 0.22–0.62) <i>P</i> < 0.001
Oaknin et al. <sup>5</sup>	January, 2022	Non-randomised phase I	All histologic types except carcinosarcoma and sarcoma	Advanced or metastatic (recurrent)	Previously treated patients	16.3 (9.5–22.1)	108	Dostarlimab 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks until disease progression	No comparator arm	43.5% (34.0–53.4)	12.2 (no CI data found)	NR (no CI data found)

Antill et al. <sup>22</sup>	June, 2021	Non-randomised phase II	All histologic types except carcinosarcoma	Advanced	Previously untreated and treated patients	19 (no range data found)	36	Durvalumab 1500 mg every 4 weeks until disease progression, prohibitive toxicity, or withdrawal	No comparator arm	47% (32–63)	8.3 (2.4–NR)	NR (no CI data found)
Oaknin et al. <sup>25</sup>	November, 2020	Non-randomised phase I	All histologic types (serous carcinoma, unspecified, mixed, undifferentiated, squamous and unknown)	Advanced or metastatic (recurrent)	Previously treated patients	11.2 (0.03–22.11)	71	Dostarlimab 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks until disease progression or unacceptable toxicity	No comparator arm	42.3% (30.6–54.6)	8.1 (3.0–18.0)	NR (no CI data found)
Makker et al. <sup>19</sup>	September, 2020	Non-randomised phase Ib/II	All histologic types (endometrioid, serous and clear-cell adenocarcinoma, undifferentiated, dedifferentiated, adenocarcinoma not otherwise specified and other, predominantly mixed histology)	Advanced or metastatic	Previously treated patients	18.7 (13.1–20.3)	11	Lenvatinib 20 mg once daily and pembrolizumab 200 mg once every 3 weeks for 35 cycles	No comparator arm	63.6% (30.8–89.1)	18.9 (4.0–NR)	NR (7.4 – NR)
Azad et al. <sup>28†‡</sup>	January, 2020	Non-randomised phase II (basket)	Endometrioid endometrial, adenocarcinoma and variants (mucinous, squamous and mucin vacuoles, squamous, prominent morula formation, mucin vacuoles, and mixed serous and mucinous)	Advanced or metastatic	Previously treated patients	17.3 (no range data found)	13	Nivolumab 3 mg/kg every 2 weeks for 28-day cycles	No comparator arm	36% (23.5–49.5) <sup>†‡</sup>	6.3 (no CI data found) <sup>†‡</sup>	17.3 (no CI data found) <sup>†‡</sup>
Marabelle et al. <sup>16</sup> (KEYNOTE-158)	January, 2020	Non-randomised phase II	All histologic types except sarcomas and mesenchymal tumours	Advanced or metastatic	Previously treated patients	13.4 (0.4–34.2)	49	Pembrolizumab 200 mg once every 3 weeks for 35 cycles	No comparator arm	57.1% (42.2–71.2)	25.7 (4.9–NR)	NR (27.2–NR)
Konstantinopoulos et al. <sup>30</sup>	October, 2019	Non-randomised, phase II	Endometrioid, serous, adenocarcinoma not otherwise specified, carcinosarcoma and mixed	Advanced or metastatic (recurrent or persistent)	Previously treated patients	18.6 (4.4–22.2)	15	Avelumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity	No comparator arm	26.7% (7.8–55.1)	4.4 (1.7–NR)	NR (no CI data found)
Makker et al. <sup>18‡</sup>	May, 2019	Non-randomised phase II	Endometrioid, serous and clear cell adenocarcinoma, serous adenocarcinoma and other adenocarcinomas not specified	Metastatic	Previously treated patients	13.3 (6.7–20.1)	53	Lenvatinib 20 mg once daily and pembrolizumab 200 mg once every 3 weeks for 35 cycles.	No comparator arm	47.2% (33.3–61.4) <sup>‡</sup>	7.4 (5.0–NR) <sup>‡</sup>	No data found <sup>‡</sup>

ORR: objective response rate; 95% CI: 95% confidence interval; OS: overall survival; PFS: progression-free survival; dMMR: mismatch repair deficiency; MMRp: mismatch repair proficiency; NR: not reached; HR: hazard ratio.

<sup>†</sup> One-sided 90% CI in ORR, OS and PFS.

<sup>‡</sup> Outcomes data of global population including dMMR and MMRp patients.

<sup>§</sup> Median not found, time at which ORR was described.

<sup>‡</sup> Outcomes data of global population with several types of tumour.



plus lenvatinib group and 12% (95% CI, 5–23) in the control group. Median PFS in group receiving pembrolizumab in combination with lenvatinib was 10.7 months (95% CI, 5.6–NR) and 3.7 months (95% CI, 3.1–4.4) in control group. Median OS was not reached in intervention group and 8.6 months (95% CI, 5.5–12.9) in the group receiving chemotherapy.

Concerning safety analysis, KEYNOTE-158 study showed that the most frequent AEs of pembrolizumab monotherapy were fatigue (14.6%), pruritus (12.9%) and diarrhoea (12.0%).<sup>16</sup> With respect to grade 3 or higher AEs, pembrolizumab was associated with increased transaminases (1.7%) and pneumonitis (1.3%). A total of 9.4% of patients in KEYNOTE-158 study discontinued treatment due to AEs. No patients died from AEs associated with treatment. In the study by Bellone<sup>15</sup>, pembrolizumab frequently caused diarrhoea (56.0%), fatigue (48.0%) and skin disorders (44.0%). In this trial, the most frequent grade 3 or higher AEs were hyperglycaemia (16.0%) and diarrhoea (12.0%). No information on discontinuations, interruptions, delays or deaths was reported. In Makker et al.,<sup>20</sup> the most common AEs of pembrolizumab-levatinib combination were hypertension (64.0%), hypothyroidism (57.4%) and diarrhoea (54.2%). Likewise, pembrolizumab-levatinib regimen showed hypertension (37.9%), weight loss (10.3%) and decreased appetite (7.9%) as predominant grade 3 or higher AEs. Furthermore, 69.2% of the population discontinued combination therapy. Two deaths occurred in the group of patients receiving pembrolizumab-levatinib.

#### Durvalumab

This IgG1  $\kappa$ -type monoclonal antibody selectively blocks the interaction of PD-L1 with PD-1 and CD80.<sup>21</sup> Two studies with durvalumab were included in this review, one of which used durvalumab-tremelimumab combination. The study by Antill<sup>22</sup> evaluated durvalumab in monotherapy for patients with dMMR ( $n = 36$ ) and MMRp ( $n = 35$ ). However, 21 dMMR patients had not received any previous line of treatment. This scientific publication was a phase II, non-randomised, single-arm trial. Follow-up of dMMR population was 19 months. Investigator-assessed ORR in dMMR group reached 47% (95% CI, 32–63). Median PFS was 8.3 months (95% CI 2.4–NR), and median OS was not reached. Durvalumab plus tremelimumab regimen was evaluated in a phase II, randomised, open-label, active comparator study.<sup>23</sup> Thirty-eight patients were assigned to the durvalumab monotherapy arm and 39 patients to the durvalumab-tremelimumab combination. dMMR was determined in 13.2% of patients treated with durvalumab monotherapy and 10.3% in population with a combination of immunotherapeutic agents. ORR at 6 months was 10.8% (90% CI, 4.8–100) in durvalumab arm and 5.3% (90% CI, 1.4–100) in durvalumab-tremelimumab scheme arm. Median PFS was similar in both arms: 1.9 months (90% CI, 1.75–Inf) for durvalumab and 2.0 months (90% CI, 1.75–Inf) for durvalumab plus tremelimumab. No OS data were found.

Immune-mediated AEs were collected in Antill et al.<sup>22</sup> highlighting thyroid disorders: hypothyroidism (14.0%) and hyperthyroidism (9.0%). Three patients discontinued treatment due to AEs. No other safety data were reported in this trial. In Rubinstein et al.,<sup>23</sup> the most frequent AEs were hyperglycemia (95% in monotherapy arm and 92% in durvalumab-tremelimumab group) and anaemia (82.0% and 87.0%, respectively). The most common grade 3 or higher AEs were: anaemia (29.0% for durvalumab and 28.0% for durvalumab-tremelimumab regimen) and decreased lymphocyte count (26.0% and 38.0%, respectively). Data on treatment reductions, discontinuations, or deaths due to AEs were not reported.

#### Dostarlimab

The mechanism of action of this IgG4 monoclonal antibody is based on binding to PD-1 receptors and blocking their association with PD-L1

and PD-L2.<sup>24</sup> A single-arm phase I trial was found. In the first published results, Oaknin et al.<sup>25</sup> included patients with MSI-H/dMMR profile. In an update by Oaknin et al.,<sup>5</sup> two cohorts were established: cohort A1 (MSI-H/dMMR,  $n = 108$ ) and cohort A2 (MMRp/MSS,  $n = 161$ ). ORR was similar in both publications: 42.3% (95% CI, 30.6–54.6) from Oaknin et al.<sup>25</sup> vs. 43.5% (95% CI, 34.0–53.4) in the A1 cohort.<sup>5</sup> In both papers, ORR was assessed by a blinded independent central committee. On the other hand, PFS was 8.1 months (95% CI, 3.0–18.0) in Oaknin et al.<sup>25</sup> versus 12.2 months (no CI data) in the most updated publication. Median OS was not reached in either study. Subsequently, a phase I single-arm trial by André et al.<sup>26</sup> enrolled patients diagnosed with different solid tumours. This trial included a post-hoc analysis presenting the results disaggregated by tumour type. For 143 patients diagnosed of EC with dMMR or mutated POLE, an independent committee determined an ORR of 45.5% (95% CI, 37.1–54.0). Median PFS was 6.0 (95% CI, 4.1–18.0) months, and median OS was not reached (95% CI, 25.7–NR).

Up to 93.9% and 95.3% of patients in Oaknin et al.<sup>25</sup> and Oaknin et al.,<sup>5</sup> respectively, experienced an AE. In patients diagnosed of EC and dMMR, the most frequent AEs were diarrhoea (15.4% and 16.3% in 2020 and 2022 studies, respectively) and asthenia (15.4% and 14.0%). Considering AEs of grade 3 or higher, anaemia was the most common in both studies (2.9% and 3.9%). A total of 23.1% of patients in Oaknin et al.<sup>25</sup> presented to discontinue treatment due to AEs. Nevertheless, in Oaknin et al.,<sup>5</sup> such discontinuations occurred in 3.9%. No deaths were recorded in dostarlimab groups in both studies.

Safety analysis in André et al.<sup>26</sup> included the overall population without differentiation by solid tumour type. The most frequent AEs were diarrhoea (15.4%) and asthenia (14.3%). Anaemia (2.5%) and increased transaminases (1.9%) were found as AEs of grade 3 or higher. Treatment discontinuations were led by AEs in 6.9% of subjects. There were two deaths attributed to treatment, but none in the population with EC and dMMR.

#### Nivolumab

Nivolumab is an IgG4 monoclonal antibody that prevents the interaction between the PD-1 receptor and PD-L1.<sup>27</sup> The study found was a phase II basket single-arm CT with several types of tumours.<sup>28</sup> Median patient follow-up was 17.3 months. The efficacy outcomes achieved by the global population were: ORR = 36% (90% CI, 23.5–49.5), median PFS = 6.3 months and median OS = 17.3 months (both outcomes without reported CIs).

Regarding safety, the most frequent AEs were fatigue (40%), anaemia (33%) and skin rash (17%). Likewise, anaemia (18.4%), dehydration (5.3%), fatigue (5.3%), maculo-papular rash (5.3%), sepsis (5.3%) and skin infections (5.3%) were the most common grade 3 or higher AEs. No data were available on treatment reductions, discontinuations or deaths due to AEs.

#### Avelumab

Avelumab is an IgG1 class monoclonal antibody that interacts with PD-L1 by preventing binding to PD-1 and B7.1.<sup>29</sup> Konstantinopoulos et al.<sup>30</sup> consisted of a phase II single-arm CT with two cohorts. The selected population was distributed according to the presence of dMMR/POLE mutated ( $n = 15$ ) or MMRp/POLE without mutations ( $n = 16$ ). The co-primary endpoints were ORR and PFS at 6 months. OS was also measured as a secondary endpoint. With a median follow-up of 18.6 months, ORR in dMMR/POLE cohort was 26.7% (95% CI, 7.8–55.1). PFS at 6 months was 40.0% (95% CI, 16.3–66.7), while the median was 4.4 (95% CI, 1.7–NR). Median OS was not reached.

Concerning safety, 71.0% of patients presented at least one AE. Fatigue (35.5%) followed by nausea (16%) were the most frequent AEs. Grade 3 or higher AEs were registered in 19.4% of cases, most frequently being: anaemia (6.5%), diarrhoea (6.5%), bradycardia (3.2%),

hypothyroidism (3.2%), myositis (3.2%) and rash acneiform (3.2%). No data were available on treatment reductions, discontinuations or deaths due to AEs.

### Risk of bias

Durvalumab presented global data from a population involving previously untreated and pre-treated patients.<sup>22</sup> Sample sizes of CTs ranged from 11 (pembrolizumab-lenvatinib regimen, Makker et al.<sup>19</sup> to 143 (dostarlimab)<sup>26</sup> patients. CTs of schemes with the smallest sample sizes were: pembrolizumab-lenvatinib combination ( $n = 11$ ),<sup>19</sup> nivolumab ( $n = 13$ ),<sup>28</sup> avelumab ( $n = 15$ ),<sup>30</sup> pembrolizumab monotherapy ( $n = 24$ )<sup>15</sup> and durvalumab ( $n = 36$ ).<sup>22</sup> Median follow-up of studies ranged from 6 (durvalumab-tremelimumab combination)<sup>23</sup> to 42.6 (pembrolizumab)<sup>14</sup> months. Follow-up period was reported by all CTs.

All of the included studies had an overall assessment of a low risk of bias when the Cochrane risk of bias assessment tool was applied. Fig. 2 shows the analysis with the risk of bias assessment tool.

### Discussion

The efficacy of pembrolizumab monotherapy and the combination of pembrolizumab plus lenvatinib in patients with advanced and/or metastatic EC with MSI-H/dMMR seems to be promising. However, rigorous therapeutic positioning is not possible with the CTs evaluated. Pembrolizumab monotherapy –with an ORR of 58%, median PFS of 23.5 months and OS of 40 months<sup>15</sup>– would be placed as the alternative with the greatest numerical effect, pending more mature data from

better-designed CTs. Pembrolizumab plus lenvatinib combination was evaluated in a higher-quality study (randomised phase III CT) with a follow-up of 12.2 months.<sup>20</sup> This regimen showed an ORR of 40% and a median PFS of 10.7 months, without reaching a median OS. In addition, durvalumab and dostarlimab have also been evaluated.<sup>22,26</sup> After a 19-month follow-up, durvalumab demonstrated an ORR of 47% and a median PFS of 8.3 months, without achieving a median OS.<sup>22</sup> These data were significantly biased, as they were obtained from a heterogeneous population including previously untreated patients. With a median follow-up of 29.1 months, dostarlimab achieved an ORR of 45.5% and a median PFS of 6 months, with a median OS not reached.<sup>26</sup> Nivolumab was evaluated in a basket design trial.<sup>28</sup> This antibody showed an ORR of 36%, median PFS of 6.3 months and OS of 17.3 months. The design of this CT mixed results from very heterogeneous pathologies, so few conclusions could be extracted from its data. On the other hand, avelumab presented poor results in dMMR patients with an ORR of 26.7% and a median PFS of 4.4 months.<sup>30</sup> With respect to safety, the most common AEs were fatigue (up to 40% of patients with nivolumab),<sup>28</sup> anaemia (33% of patients with nivolumab)<sup>28</sup> and gastrointestinal AEs (up to 16% of patients experienced nausea with avelumab,<sup>30</sup> and 16.3% diarrhoea with dostarlimab<sup>5,25</sup>). Anaemia was the most frequent grade 3 or higher AE, particularly with durvalumab (29% of patients).<sup>22</sup> About immunotherapy combinations, pembrolizumab plus lenvatinib appeared to show numerically superior efficacy data compared to durvalumab plus tremelimumab.<sup>18–20,23</sup> The absence of common comparators prevents the confirmation of these numerical differences for proper a reliable therapeutic positioning. Likewise, the combination of pembrolizumab plus lenvatinib has not yet demonstrated a clear benefit




Figure 2. Cochrane risk of bias assessment tool.

over pembrolizumab monotherapy in patients with MSI-H/dMMR.<sup>16,20</sup> In fact, ORR was lower with the combination regimen (40% vs 58%). PFS and OS values would be in favour of pembrolizumab monotherapy. Nevertheless, these comments are simple numerical comparisons. The current design and median follow-up of the CTs do not allow for rigorous efficacy comparisons. In addition, the combination of pembrolizumab with lenvatinib shows a worse safety profile given the higher number of treatment discontinuations compared to monotherapy.<sup>16,20</sup>

Some of the studies designed two cohorts based on the different MS repair capacity. A tumour characterised as MSI-H could be considered as dMMR. Similarly, a neoplasm determined as MSI-L or MSS could be assessed as MMRp. However, the criterion for classifying a tumour as MMS or MSI-L is not clearly defined.<sup>6,7</sup> In CTs that performed analyses according to MS repair, MSI-H/dMMR populations suggested better results with immunotherapy than those with MSS/MMRp. MSI-H/dMMR tumours are associated with increased tumour neoantigen load, lymphocyte infiltration and increased PD-1 and PD-L1 expression.<sup>9</sup> This leads to an overexpression of the immune response. Despite this, patients with MSS/MMRp tumours may also benefit from the use of some immunotherapy regimens over chemotherapy, as can be seen in the subgroup analysis of Makker et al.<sup>20</sup>

CTs included in this review generally recruited a small sample size of patients diagnosed with EC and MSI. The lower likelihood of finding patients with MSI-H/dMMR profile makes it difficult to reliably detect differences in drug response compared to the MSS/MMRp population.<sup>31</sup> This is essential to develop a correct subgroup analysis for each of the therapeutic alternatives. Approvals by the European Medicines Agency (EMA) are currently based on results from CT in patients with MSI-H/dMMR. On 25 February 2021, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for dostarlimab as monotherapy for the treatment of adult patients with MSI-H/dMMR who have progressed during or after prior treatment with a platinum-based regimen.<sup>32</sup> On 24 March 2022, pembrolizumab received a positive CHMP opinion for the same indication.<sup>33</sup>

Our review included EC previously treated with at least one prior line of primarily platinum-based regimens. Recent publications such as Mirza et al.<sup>34</sup> and Eskander et al.<sup>35</sup> used dostarlimab and pembrolizumab, respectively, combined with chemotherapy in naïve patients. Mirza et al.<sup>34</sup> included 118 patients with dMMR: 53 cases received dostarlimab plus chemotherapy and 65 patients were assigned to the chemotherapy group. Results in dostarlimab plus chemotherapy arm were superior in terms of OS and PFS compared to control arm. Eskander et al.<sup>35</sup> conducted a study similar to Mirza et al.<sup>34</sup> They enrolled 225 previously untreated patients with MSI-H/dMMR: 112 cases received pembrolizumab-chemotherapy scheme and 113 patients received chemotherapy. After 12 months of follow-up, median PFS was not reached in pembrolizumab plus chemotherapy arm compared to 7.6 months in the control group.

Limitations of the included CTs are small sample sizes and lack of comparators in most of the studies. Only Rubinstein et al.<sup>23</sup> and Makker et al.<sup>20</sup> developed a comparative design and none of the studies reported a common comparator. Single-arm studies make it difficult to extrapolate results to clinical practice. The lack of randomisation does not allow adjustment for the effect of unknown benefit-related factors. Moreover, adjustment for a few known factors that influence outcomes has limitations. Lack of stratification or heterogeneous populations in non-randomised trials can lead to significant bias in indirect comparisons. Therefore, the establishment of reliable indirect comparisons requires common comparator drugs for proper therapeutic positioning. Adjusted indirect comparisons or network meta-analyses require common treatments such as comparator linkages. In addition, no mature results on an endpoint such as OS have been obtained in some of the trials discussed. Even no OS data were detailed in other CTs. On the other hand, ORR is a surrogate endpoint that could lead to bias and it was frequently used as a primary endpoint. Therefore, some trials –such as Oaknin et al.<sup>5</sup> and Marabelle et al.<sup>16</sup>– incorporated an independent

committee to assess ORR and reduce the subjective influence of investigators.

Subgroup analyses should be carefully designed. A minimum sample size of 50 patients per arm is required to assess the results for each factor evaluated.<sup>36</sup> In our review, we found only three trials with more than 100 patients.<sup>5,20,26</sup> In order to interpret outcomes by subgroups, it would be advisable to design larger comparative studies exclusively for the population of EC with MSI previously treated with platinum-based chemotherapy. In this way, subgroup analyses could be developed within these CTs that could adequately assess the impact of biomarkers such as PD-1 or PD-L1. Until now, the contribution of results according to PD-L1 expression is almost non-existent. There are some cases where low-quality data were reported from heterogeneous populations or mixing of multiple biomarkers. André et al.<sup>26</sup> presented ORR by biomarker status in a combined analysis of patients with dMMR solid tumours (not exclusively of our target population with EC). The results were described according to tumour mutational burden (TMB) and PD-L1: TMB-high/PD-L1-high tumours had ORR (60.4%), TMB-low/PD-L1-low (25.0%), TMB-high/PD-L1-low (32.3%) and TMB-low/PD-L1-high (42.9%). These data are difficult to compare with the rest of the data from other trials.

Characterisation of the MS profile in EC could be important to identify which patients may benefit most from treatments. However, comparative phase III trials are essential to correctly position the results of all therapeutic alternatives. Few CTs have shown mature data in OS. Studies with larger sample size, longer follow-up and better designs are needed, as well as appropriately designed subgroup analyses based on differences in MS repair mechanisms.

## Presentación en Congresos

No se ha presentado en ningún congreso con anterioridad.

## Conflicts of interest

Gil-Sierra Manuel David: advisory board membership (consultancy fees) for Janssen Pharmaceutica and reimbursement for symposium attendance for Pfizer for other cancer drugs. The rest of the authors have no conflict of interest to declare.

Todos los autores aprobaron la versión final que se envía como manuscrito, con la intención de ser publicado. Se declara que los autores han leído y aprobado el manuscrito, y se cumplen los requisitos para la autoría:

- Moreno-Ramos Cristina: Concepción y diseño del estudio, búsqueda y tratamiento de los datos, interpretación clínica de los datos, búsqueda de bibliografía sobre el estudio y antecedentes, elaboración del manuscrito, así como de su revisión y gestión de envío, aprobación final de la versión que se publicará.
- Gil-Sierra Manuel David: Concepción y diseño del estudio, búsqueda y tratamiento de los datos, interpretación clínica de los datos, búsqueda de bibliografía sobre el estudio y antecedentes, elaboración del manuscrito, así como de su revisión y gestión de envío, aprobación final de la versión que se publicará.
- Briceño-Casado Maria del Pilar: Concepción y diseño del estudio, búsqueda y tratamiento de los datos, interpretación clínica de los datos, búsqueda de bibliografía sobre el estudio y antecedentes, elaboración del manuscrito, así como de su revisión y gestión de envío, aprobación final de la versión que se publicará.

Además de las actividades descritas anteriormente, todos los autores confirman haber formado parte de las siguientes contribuciones:

- La concepción y el diseño del trabajo, o a la recogida de datos, o al análisis y la interpretación de los datos.
- La escritura del artículo o su revisión crítica con importantes contribuciones intelectuales.



- La aprobación de la versión final para su publicación.
- Hacerse responsable y garante de que todos los aspectos que integran el manuscrito han sido revisados y discutidos entre los autores con la finalidad de que sean expuestos con la máxima precisión e integridad.

## Responsabilidad y cesión de derechos

La cláusula es aceptada por todos los autores firmantes del manuscrito.

Los/las autores/as declaran explícitamente que el trabajo no ha sido publicado previamente, ni se encuentra en proceso de revisión en ninguna otra revista.

Los autores declaran que se han tenido en cuenta las instrucciones para autores y las responsabilidades éticas y, entre ellas, que todos los autores firmantes cumplen los requisitos de autoría y que todos han declarado sus respectivos conflictos de intereses.

Se cumplieron todas las responsabilidades éticas necesarias en lo referente a autoría y publicación redundante (la protección de personas y animales de investigación, así como el consentimiento informado no fueron necesarios por el diseño del estudio).

Todos los autores aceptamos la responsabilidad definida por el Comité Internacional de Editores de Revistas Médicas (disponible en <http://www.icmje.org/>).

Los autores cedemos, en el supuesto de publicación, de forma exclusiva los derechos de reproducción, distribución, traducción y comunicación pública (por cualquier medio o soporte sonoro, audiovisual o electrónico) de nuestro trabajo a Farmacia Hospitalaria y por extensión a la SEFH. Para ello se firmará una carta de cesión de derechos en el momento del envío del trabajo a través del sistema online de gestión de manuscritos.

## CRediT authorship contribution statement

**Cristina Moreno-Ramos:** Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. **Manuel David Gil-Sierra:** Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. **María del Pilar Briceño-Casado:** Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.

## Acknowledgments

This study was funded as “Research Project” for one of the “Grants 2023” from the Andalusian Hospital Pharmacy Foundation of the Andalusian Society of Hospital Pharmacists.

## References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209–49. doi:10.3322/caac.21660.
- Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. *JCO Precis Oncol*. 2017;2017:PO.17.00073. doi:10.1200/PO.17.00073.
- Li K, Luo H, Huang L, Luo H, Zhu X. Microsatellite instability: a review of what the oncologist should know. *Cancer Cell Int*. 2020;20:16. doi:10.1186/s12935-019-1091-8.

4. Ahadova A, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, et al. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. *Int J Cancer*. 2018;143(1):139–50. doi:10.1002/ijc.31300.
5. Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. *J Immunother Cancer*. 2022;10(1):e003777. doi:10.1136/jitc-2021-003777.
6. De la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. *J Clin Oncol*. 2010;28(20):3380–7. doi:10.1200/JCO.2009.27.0652.
7. Mueller J, Gazzoli I, Bandipalliam P, Garber JE, Syngal S, Kolodner RD. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. *Cancer Res*. 2009;69(17):7053–61. doi:10.1158/0008-5472.CAN-09-0358.
8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines). Uterine neoplasms. Version 2.2024; 2024 [accessed 6 June 2024]. Available in: [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf).
9. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-unstable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. *JAMA Oncol*. 2015;1(9):1319–23. doi:10.1001/jamaoncol.2015.2151.
10. Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. *BMC Health Serv Res*. 2014;14:579. doi:10.1186/s12913-014-0579-0.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6:e1000097. doi:10.1371/journal.pmed.1000097.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1). *Eur J Cancer Oxf Engl*. 2009;45:228–47. doi:10.1016/j.ejca.2008.10.026.
13. Cochrane methods bias. Risk Of Bias In Non-randomized Studies of Interventions, Version 2 (ROBINS-I V2); 2025 [accessed 5 March 2025]. Available in: <https://methods.cochrane.org/bias/risk-bias-nonrandomized-studies-interventions>.
14. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. *J Clin Oncol*. 2022;40(7):752–61. doi:10.1200/JCO.21.01874.
15. Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. *Cancer*. 2022;128(6):1206–18. doi:10.1002/cncr.34025.
16. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol*. 2020;38(1):1–10. doi:10.1200/JCO.19.02105.
17. Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. *Ann Oncol*. 2022;33(9):929–38. doi:10.1016/j.annonc.2022.05.519.
18. Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol*. 2019;20(5):711–8. doi:10.1016/S1470-2045(19)30020-8.
19. Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. *J Clin Oncol*. 2020;38(26):2981–92. doi:10.1200/JCO.19.02627.
20. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med*. 2022;386(5):437–48. doi:10.1056/NEJMoa2108330.
21. Spanish Agency for Medicines and Health Products. Technical label of durvalumab (Imfinzi®); 2023 [accessed 15 May 2023]. Available in: [https://cima.aemps.es/cima/pdfs/ft/1181322001/FT\\_1181322001.pdf](https://cima.aemps.es/cima/pdfs/ft/1181322001/FT_1181322001.pdf).
22. Antill Y, Kok PS, Robledo K, Yip S, Cummins M, Smith D, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer: a nonrandomized phase 2 clinical trial. *J Immunother Cancer*. 2021;9(6):e002255. doi:10.1136/jitc-2020-002255.
23. Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, et al. Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: a randomized open-label phase 2 study. *Gynecol Oncol*. 2023;169:64–9. doi:10.1016/j.ygyno.2022.11.028.
24. Spanish Agency for Medicines and Health Products. Technical label of dostarlimab (Jemperli®); 2023 [accessed 20 May 2023]. Available in: [https://cima.aemps.es/cima/dochtml/ft/1211538001/FT\\_1211538001.html](https://cima.aemps.es/cima/dochtml/ft/1211538001/FT_1211538001.html).
25. Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. *JAMA Oncol*. 2020;6(11):1766–72. doi:10.1001/jamaoncol.2020.4515.

26. André T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. *JAMA Netw Open*. 2023;6(11): e2341165. doi:10.1001/jamanetworkopen.2023.41165.
27. Spanish Agency for Medicines and Health Products. Technical label of nivolumab (Opdivo®); 2020 [accessed 20 May 2023]. Available in: [https://cima.aemps.es/cima/pdfs/ft/1151014001/FT\\_1151014001.pdf](https://cima.aemps.es/cima/pdfs/ft/1151014001/FT_1151014001.pdf).
28. Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. *J Clin Oncol*. 2020;38(3):214–22. doi:10.1200/JCO.19.00818.
29. Spanish Agency for Medicines and Health Products. Technical label of avelumab (Bavencio®); 2020 [accessed 20 May 2023]. Available in: [https://cima.aemps.es/cima/dochtml/ft/1171214001/FT\\_1171214001.html](https://cima.aemps.es/cima/dochtml/ft/1171214001/FT_1171214001.html).
30. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. *J Clin Oncol*. 2019;37(30):2786–94. doi:10.1200/JCO.19.01021.
31. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. *Clin Cancer Res*. 2016;22(4):813–20. doi:10.1158/1078-0432.CCR-15-1678.
32. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of opinion (initial authorisation) for dostarlimab (Jemperli®); 2021 [accessed 5 June 2023]. Available in: [https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jemperli\\_en.pdf](https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-jemperli_en.pdf).
33. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of opinion (post authorisation) for pembrolizumab (Keytruda®); 2022 [accessed 5 June 2023]. Available in: [https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-109-ii-117\\_en.pdf](https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-109-ii-117_en.pdf).
34. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. *N Engl J Med*. 2023;388(23):2145–58. doi:10.1056/NEJMoa2216334.
35. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N Engl J Med*. 2023;388(23):2159–70. doi:10.1056/NEJMoa2302312.
36. Gil-Sierra MD, Fénix-Caballero S, Abdel Kader-Martin L, Fraga-Fuentes MD, Sánchez-Hidalgo M, Alarcón de la Lastra-Romero C, et al. Checklist for clinical applicability of subgroup analysis. *J Clin Pharm Ther*. 2020;45(3):530–8. doi:10.1111/jcpt.13102.